Bafna Pharmaceuticals (BAFNAPH) Q2 24/25 earnings summary

Executive summary

• Unaudited financial results for the quarter and half year ended September 30, 2024, were approved and reviewed by the Board and auditors on November 11, 2024.

• The company operates in a single segment: pharmaceutical manufacturing.

Financial highlights

• Revenue from operations for Q2 FY25 was ₹4,032.31 lakhs, up from ₹3,328.63 lakhs in Q1 FY25 and ₹4,067.82 lakhs in Q2 FY24.

• Net profit for Q2 FY25 was ₹261.74 lakhs, compared to a net loss of ₹72.36 lakhs in Q1 FY25 and a profit of ₹248.39 lakhs in Q2 FY24.

• Total income for H1 FY25 was ₹8,262.53 lakhs, with a net profit of ₹252.22 lakhs.

• Basic and diluted EPS for Q2 FY25 stood at ₹1.11, compared to ₹(0.31) in Q1 FY25.

Outlook and guidance

• Promoters are working to regularize statutory compliances and maintain minimum public shareholding as per regulations.